While the author of today’s article acknowledges that “biotech investors…tend not to be a squeamish bunch”, he observes that the “looming presidential election could still cause them some visceral discomfort.” Recalling the 2016 presidential campaign, in which both major candidates’ rhetoric regarding drug pricing caused biotech stocks to plummet, he advises that “investors shouldn’t dismiss the possibility of another election-related selloff” this time. So how can biotech investors survive – or, better yet, take advantage of – this election season? CLICK HERE.
